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Aurora kinase A (AURKA) plays a pivotal role in the mitotic processes during cell division. We previously 
showed that AURKA was aberrantly expressed in hematological malignant cells including those from acute 
myelogenous leukemia (AML), compared to bone marrow mononuclear cells (BMMCs) isolated from healthy 
volunteers. We have recently shown that CD34+/CD38- AML cells, enriched for leukemia stem cells (LSCs), 
were relatively resistant to cytarabin-mediated growth inhibition compared to their CD34+/CD38+ counterparts.
This study attempted to identify therapeutic targets in CD34+/CD38- AML cells and found that freshly isolated 
CD34+/CD38- AML cells from patients (n=12) expressed a greater amount of AURKA than their CD34+/CD38+
counterparts, as well as CD34+ normal hematopoietic stem/progenitor cells (HSCs) isolated from healthy 
volunteers (n=6) as measured by real time RT-PCR. Blockade of AURKA by a specific inhibitor MLN8237 
significantly inhibited proliferation and induced apoptosis of CD34+/CD38- AML cells in association with 
downregulation of anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 and increase in Bax/Bcl-2 ratio. 
Importantly, inhibition of AURKA in CD34+/CD38- AML cells by MLN8237 significantly impaired engraftment 
of these cells in severly immunocompromised mice and prolonged their survival. Moreover, MLN8237 potently 
inhibited proliferation of engrafted human AML cells in association with reduction in a population of 
CD34+/CD38- AML cells in murine BMs and spleens. Taken together, AURKA may be a promising molecular 
target to eliminate chemotherapy-resistant CD34+/CD38- AML cells.
